MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Search

Denali Therapeutics Inc

Затворен

СекторЗдравеопазване

18.21 0.61

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.77

Максимум

18.47

Ключови измерители

By Trading Economics

Приходи

-2.8M

-127M

Служители

517

EBITDA

-12M

-134M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+80.28% upside

Дивиденти

By Dow Jones

Следващи печалби

25.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

557M

2.8B

Предишно отваряне

17.6

Предишно затваряне

18.21

Настроения в новините

By Acuity

50%

50%

151 / 361 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Denali Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.01.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15.01.2026 г., 00:00 ч. UTC

Печалби

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14.01.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14.01.2026 г., 23:39 ч. UTC

Пазарно говорене

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14.01.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14.01.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14.01.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14.01.2026 г., 22:09 ч. UTC

Печалби

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14.01.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Announces Positive Profit Alert for 2025

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Citigroup Acting as Financial Advisor to WuXi XDC

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Aims to Keep Listing Status of BioDlink

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.01.2026 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Makes Cash Offer for BioDlink International

14.01.2026 г., 21:13 ч. UTC

Пазарно говорене

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14.01.2026 г., 20:30 ч. UTC

Пазарно говорене
Печалби

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14.01.2026 г., 20:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14.01.2026 г., 20:08 ч. UTC

Пазарно говорене

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14.01.2026 г., 19:33 ч. UTC

Пазарно говорене

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14.01.2026 г., 19:06 ч. UTC

Пазарно говорене
Печалби

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Denali Therapeutics Inc Прогноза

Ценова цел

By TipRanks

80.28% нагоре

12-месечна прогноза

Среден 32.36 USD  80.28%

Висок 40 USD

Нисък 25 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Denali Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

13

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

13.355 / 16.44Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

151 / 361 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat